Himanshu Joshi1, Sylvia Lin2, Kezhen Fei3, Anne S Renteria4, Hannah Jacobs2, Madhu Mazumdar1, Sundar Jagannath4, Nina A Bickell5. 1. Institute for Healthcare Delivery Science, NY, NY, United States; Department of Population Health Science and Policy, NY, NY, United States; Tisch Cancer Institute all at the Icahn School of Medicine at Mount Sinai, NY, NY, United States. 2. Department of Population Health Science and Policy, NY, NY, United States. 3. Department of Population Health Science and Policy, NY, NY, United States; Tisch Cancer Institute all at the Icahn School of Medicine at Mount Sinai, NY, NY, United States. 4. Department of Hematology and Medical Oncology, NY, NY, United States. 5. Department of Population Health Science and Policy, NY, NY, United States; Center for Health Equity and Community Engaged Research, NY, NY, United States; Tisch Cancer Institute all at the Icahn School of Medicine at Mount Sinai, NY, NY, United States. Electronic address: nina.bickell@mountsinai.org.
Abstract
PURPOSE: Multiple Myeloma (MM), the second leading blood malignancy, has complex and costly disease management. We studied patterns of treatment disparities and unplanned interruptions among the MM patients after the Affordable Care Act to assess their prevalence and effect on survival. MATERIALS AND METHODS: This retrospective study of 1002 MM patients at a tertiary referral center used standard guidelines as a reference to identify underuse of effective treatments. We used multivariate logistic regression and Cox proportionate hazard to study the prognostic effect on survival. RESULTS: Median age in the cohort was 63.0 [IQR: 14] years. Non-Hispanic White (NHW) patients were older (p = 0.007) and more likely to present with stage I disease (p = 0.02). Underuse of maintenance therapy (aOR = 1.98; 95 % CI 1.12-3.48) and interruptions in treatment were associated with race/ethnicity and insurance (aOR = 4.14; 95 % CI: 1.78-9.74). Only underuse of induction therapy was associated with overall patient survival. CONCLUSION: Age, race, ethnicity and primary insurance contribute to the underuse of treatment and in unplanned interruptions in MM treatment. Addressing underuse causes in such patients is warranted.
PURPOSE: Multiple Myeloma (MM), the second leading blood malignancy, has complex and costly disease management. We studied patterns of treatment disparities and unplanned interruptions among the MM patients after the Affordable Care Act to assess their prevalence and effect on survival. MATERIALS AND METHODS: This retrospective study of 1002 MM patients at a tertiary referral center used standard guidelines as a reference to identify underuse of effective treatments. We used multivariate logistic regression and Cox proportionate hazard to study the prognostic effect on survival. RESULTS: Median age in the cohort was 63.0 [IQR: 14] years. Non-Hispanic White (NHW) patients were older (p = 0.007) and more likely to present with stage I disease (p = 0.02). Underuse of maintenance therapy (aOR = 1.98; 95 % CI 1.12-3.48) and interruptions in treatment were associated with race/ethnicity and insurance (aOR = 4.14; 95 % CI: 1.78-9.74). Only underuse of induction therapy was associated with overall patient survival. CONCLUSION: Age, race, ethnicity and primary insurance contribute to the underuse of treatment and in unplanned interruptions in MM treatment. Addressing underuse causes in such patients is warranted.
Authors: Vishal Bhatnagar; Yin Wu; Olga G Goloubeva; Kathleen T Ruehle; Todd E Milliron; Carolynn G Harris; Aaron P Rapoport; Saul Yanovich; Edward A Sausville; Maria R Baer; Ashraf Z Badros Journal: Cancer Date: 2014-12-02 Impact factor: 6.860
Authors: Scott F Huntington; Brendan M Weiss; Dan T Vogl; Adam D Cohen; Alfred L Garfall; Patricia A Mangan; Jalpa A Doshi; Edward A Stadtmauer Journal: Lancet Haematol Date: 2015-09-17 Impact factor: 18.959
Authors: Adam J Olszewski; Stacie B Dusetzina; Charles B Eaton; Amy J Davidoff; Amal N Trivedi Journal: J Clin Oncol Date: 2017-05-25 Impact factor: 50.717
Authors: Saad Z Usmani; Antje Hoering; Michele Cavo; Jesus San Miguel; Hartmut Goldschimdt; Roman Hajek; Ingemar Turesson; Juan Jose Lahuerta; Michel Attal; Bart Barlogie; Jae Hoon Lee; Shaji Kumar; Stig Lenhoff; Gareth Morgan; S Vincent Rajkumar; Brian G M Durie; Philippe Moreau Journal: Blood Cancer J Date: 2018-11-23 Impact factor: 11.037
Authors: Sikander Ailawadhi; Ryan D Frank; Pooja Advani; Abhisek Swaika; M'hamed Temkit; Richa Menghani; Mayank Sharma; Zahara Meghji; Shumail Paulus; Nandita Khera; Shahrukh K Hashmi; Aneel Paulus; Tanya S Kakar; David O Hodge; Dorin T Colibaseanu; Michael R Vizzini; Vivek Roy; Gerardo Colon-Otero; Asher A Chanan-Khan Journal: Cancer Med Date: 2017-11-03 Impact factor: 4.452